Share this article
Core Scientific Holders Poised to Reject CoreWeave Merger, Jefferies Says
The bank said investors are likely to vote down the deal on Oct. 30, betting Core Scientific can create more value on its own.
Updated Oct 29, 2025, 11:21 a.m. Published Oct 29, 2025, 11:21 a.m.
What to know:
- Jefferies expects Core Scientific shareholders to reject the CoreWeave merger as CORZ trades 18% above the implied offer.
- CORZ can drive value independently with 305 MW of capacity and strong AI data center demand.
- The bank raised its price target to $24 from $22 and reiterated its buy rating on the shares, citing confidence in Core Scientific’s standalone growth potential
Investment bank Jefferies said Core Scientific (CORZ) shareholders appear poised to reject the proposed merger with CoreWeave (CRWV) when they vote on Oct. 30, as CORZ shares are trading roughly 18% above the implied offer price.
The premium suggests investors see the deal as undervaluing Core Scientific, and unless CoreWeave’s stock rallies sharply, Jefferies expects a no outcome, the bank said in a report on Tuesday.
STORY CONTINUES BELOW
Don't miss another story.Subscribe to the Crypto Daybook Americas Newsletter today. See all newsletters
Proxy advisor ISS and major shareholder Two Seas Capital have urged investors to reject the deal, citing valuation concerns and structural flaws.
Core Scientific’s valuation remains complex. Adjusted for land banks and bitcoin mining operations, CORZ trades roughly in line with Applied Digital (APLD), well below Cipher Mining (CIFR), and above TeraWulf (WULF), showing mixed signals on whether it’s cheap or fully valued, analysts Jonathan Petersen and Jan Aygul wrote.
The analysts argued that even if the deal collapses, Core Scientific is well positioned to create value on its own. With 305 megawatts (MW) of billable IT load available, the company could lease capacity to CoreWeave or attract a new hyperscale or “neocloud” tenant, validating its pivot to high-performance computing.
Additional leasing, power expansion, or new site acquisitions could lift its valuation, and Jefferies said a future transition to a REIT model could unlock further upside.
Still, the report cautioned that a failed vote could complicate Core Scientific’s relationship with CoreWeave, potentially making new tenants hesitant to commit. Nonetheless, CoreWeave’s growing demand for GPU capacity could still bring the companies back to the table.
Reflecting its confidence in Core Scientific’s standalone prospects, the bank's analyst raised their price target to $24 from $22.
Core Scientific shares were 1.7% higher in early trading, around $20.44.
Read more: Bitcoin Miner Core Scientific Upgraded to Buy on AI Data Center Boom: H.C. Wainwright
AI Disclaimer: Parts of this article were generated with the assistance from AI tools and reviewed by our editorial team to ensure accuracy and adherence to our standards. For more information, see CoinDesk's full AI Policy.
More For You
What to know:
- As of October 2025, GoPlus has generated $4.7M in total revenue across its product lines. The GoPlus App is the primary revenue driver, contributing $2.5M (approx. 53%), followed by the SafeToken Protocol at $1.7M.
- GoPlus Intelligence's Token Security API averaged 717 million monthly calls year-to-date in 2025 , with a peak of nearly 1 billion calls in February 2025. Total blockchain-level requests, including transaction simulations, averaged an additional 350 million per month.
- Since its January 2025 launch , the $GPS token has registered over $5B in total spot volume and $10B in derivatives volume in 2025. Monthly spot volume peaked in March 2025 at over $1.1B , while derivatives volume peaked the same month at over $4B.
More For You
Bitcoin’s Deep Correction Sets Stage for December Rebound, Says K33 Research
K33 Research says market fear is outweighing fundamentals as bitcoin nears key levels. December could offer an entry point for bold investors.
What to know:
- K33 Research says bitcoin’s steep correction shows signs of bottoming, with December potentially marking a turning point.
- The firm has argued that the market is overreacting to long-term risks while ignoring near-term signals of strength, like low leverage and solid support levels.
- With likely policy shifts ahead and cautious positioning in futures, K33 sees more upside potential than risk of another major collapse.
Top Stories
